Arkin Capital Closes $100M Arkin Bio Ventures III to Back Advanced Pre-Clinical to Early Clinical-Stage Biotech Companies
What You Should Know:
– Arkin Capital, a leading multi-asset investment manager, today announced the closing of Arkin Bio Ventures III, a $100 million fund focused on investing in advanced pre-clinical and early clinical-stage biotech…
Continue Reading
